BLASUBCUTANEOUSINJECTABLEPriority Review
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
30/100
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
Bispecific CD20-directed CD3 T Cell Engager
Indications (9)
refractory diffuse large B-cell lymphoma (DLBCL)not otherwise specifiedincluding DLBCL arising from indolent lymphomahigh-grade B-cell lymphoma after twomore lines of systemic therapycombination with lenalidomiderituximab for the treatment of adult patients with relapsedrefractory follicular lymphoma (FL)lymphoma